Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib Plus Durvalumab in Advanced Intrahepatic Cholangiocarcinoma
NCT06728410Phase 2Recruiting
- Start
- Jan 2026
- Primary completion
- Jul 2027
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Antibody Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemigatinib and durvalumab in intrahepatic cholangiocarcinoma (ICC). Primary endpoint: Confirmed Objective Response Rate at 24 months. Started Jan 2026; status: recruiting.
02
Drugs
pemigatinibdurvalumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT06728410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06728410.